secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alpha Cognition Inc. (ACOG)
CIK:        0001655923
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001013762-24-002122
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alpha Cognition gets FDA approval for ZUNVEYL to treat mild-to-moderate Alzheimer's
--------------------------------------------------------------------------------

- FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease; second oral AD therapy approved this decade.
- GI adverse events under 2% and no insomnia observed in bioequivalence studies, designed to bypass GI absorption.
- Commercial availability planned in pharmacies nationwide starting Q1 2025.
- CEO Michael McFadden called approval a major breakthrough; company targets tolerability issues leading to 55% discontinuation rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655923/000101376224002122/0001013762-24-002122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655923/000101376224002122/ea0210215-8k_alpha.htm
  HTML page:      https://secwatch.observer/filing/0001013762-24-002122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer